Oral Cannabidiol Effects and Pharmacokinetics in Connemara Ponies

Table 3_Metabolic effects and pharmacokinetics of oral cannabidiol (CBD) in Connemara ponies following 21 days of treatment.docx contains data from a study of 13 Connemara ponies, seven with equine metabolic syndrome (EMS). The dataset, authored by Kata Wermer and last updated in May 2026, likely contains metabolic parameters and pharmacokinetic measurements from a 21-day oral CBD treatment trial.

Use Cases

• Analyze insulin response changes based on oral sugar test results mentioned in the description
• Model CBD pharmacokinetics based on reported Cmax, Tmax, and accumulation ratio
• Compare metabolic parameter trends between CBD-treated and control groups
• Assess safety and tolerability of oral CBD in ponies based on monitored clinical parameters

Strengths

• Data includes a controlled trial with 13 subjects stratified by EMS status and age
• Study reports specific pharmacokinetic results, including a Cmax increase from 22.79 ng/mL to 39.93 ng/mL and an accumulation ratio of 2.75
• Treatment duration of 21 days allows for observation of steady-state effects, reached within 4–5 days

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small at 19.7 KB, indicating limited scope

Provenance

Source

figshare

Collection Method

Experimental study involving oral CBD administration, blood sampling, and metabolic parameter measurement.

Freshness

Last updated 2026-05-14 04:25:27; freshness should be verified